The Cooper Companies, Inc.(COO)

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides medical devices, fertility, genomics, diagnostics, and contraception to health care professionals and patients worldwide. It offers surgical and office products, including PARAGARD, uterine manipulators, retractors, closure products, point of care products, LEEP products, endosee, and illuminate and fetal pillows; fertility products and services, such as fertility consumables and equipment, and embryo options and preimplantation genetic testing. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Latest News & Analysis

Cooper Companies Launches Strategic Review: Jana Partners Wins in Record Time
Cooper Companies announced a strategic review 19 days after Jana Partners' campaign, appointing a new Board Chair with divestiture expertise.

Jana Partners Targets Cooper Companies for Breakup: The Case Against Diversification
Activist investor Jana Partners has taken a $167 million stake in Cooper Companies, pushing for a separation of its contact lens and women's health businesses.
CooperCompanies (COO): Financial Growth & Strategy in 2025
A comprehensive intraday analysis of CooperCompanies' financial performance, strategic acquisitions, and market trends driving growth in 2025.
CooperCompanies: Analyzing Financial Performance and Future Growth in 2025
CooperCompanies' recent performance analyzed: earnings, international revenue, acquisitions, and industry trends shaping its 2025 outlook.
CooperCompanies (COO): Q1 2025 Outlook and Market Analysis
CooperCompanies faces mixed market signals amid acquisition rumors and competitive pressures. Q1 2025 outlook and strategic shifts analyzed.
CooperCompanies (COO): Q1 2025 Earnings Preview and Market Outlook
CooperCompanies (COO) navigates the medical device landscape amidst Q1 2025 earnings preview and strategic market positioning. Stay informed with data-driven insights.
CooperCompanies: Strategic Outlook and Market Analysis
CooperCompanies (COO) gears up for Q1 2025 earnings amid strategic growth and market shifts. Revenue focus sharpens as acquisitions and global trends steer outlook.
CooperCompanies (COO): Q1 2025 Earnings Preview and Analysis
Comprehensive analysis of The Cooper Companies (COO) ahead of Q1 2025 earnings, examining market trends, financial health, and strategic initiatives.
CooperCompanies (COO) Q1 2025 Earnings Preview: Acquisition Impact
A comprehensive analysis of CooperCompanies' Q1 2025 earnings preview, acquisition impacts, and strategic market positioning. Key insights for investors and analysts.
CooperCompanies (COO) Q1 2025 Earnings Preview: Navigating Growth in Vision Care & Women's Health
CooperCompanies (COO) Q1 2025 earnings preview: Navigating mixed market signals, strategic acquisitions, and international expansion. Key insights for investors.
CooperCompanies (COO) Q1 2025 Earnings Preview: Market Trends and Analysis
CooperCompanies (COO) prepares for Q1 2025 earnings amid market shifts. This analysis covers segments, acquisitions, trends, and expectations, offering key insights for investors.
Cooper Companies (COO) Q1 2025 Earnings: Revenue Miss Signals Challenges Ahead?
Cooper Companies' Q1 2025 earnings revealed a revenue miss despite matching EPS estimates. CooperVision's growth contrasts with CooperSurgical's challenges.
The Cooper Companies (COO) Q2 2025 Earnings: A Deep Dive
Analyzing The Cooper Companies' Q2 2025 results, market reaction, strategic initiatives, and valuation amidst industry trends and global trade dynamics.
The Cooper Companies (COO): Earnings Beat vs. Lowered Guidance
Cooper Companies' Q2 2025 earnings beat was overshadowed by lowered full-year guidance, sparking investor concern. We delve into key drivers.
The Cooper Companies (COO) Q2 2025 Analysis: Fertility Market Softness, Inventory Impact, and Strategic Positioning
Comprehensive Q2 2025 analysis of The Cooper Companies (COO) covering fertility softness, inventory pressures, tariffs, competitive landscape, and financial performance insights.
The Cooper Companies (COO) Latest Analysis: Q3 Earnings Outlook and Strategic Growth Insights
Explore The Cooper Companies' Q3 earnings outlook, analyst upgrades, and strategic growth drivers shaping COO's competitive position and financial trajectory.
The Cooper Companies (COO): Strong FY2024 Profit Lift, But Fertility Headwinds and Tariffs Cloud Near-Term Visibility
CooperCompanies posted **FY2024 revenue of $3.90B (+8.64%)** and **net income of $392.3M (+33.36%)**; CooperVision drives growth while CooperSurgical and tariff/destocking pressures create near-term uncertainty.
The Cooper Companies (COO): Earnings Strength, Heavy FCF Reinvestment, and a Capital-Allocation Crossroads
CooperCompanies posted **FY2024 revenue of $3.90B (+8.66%)** and **net income of $392.3M (+33.36%)**; the story is improving margins funded by heavy capex and M&A with a net-debt/EBITDA of ~2.32x.